• Compare Bcl-2 Inhibitors
  • Research Area

Bcl-2 Inhibitors | Activators (10)


Cat.No. Product Name Information Product Citations Customer Reviews
S1002 ABT-737 ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
  • Nat Biotechnol, 2011, 29(6):542-6
  • Nat Med, 2013, 19(11):1478-88
  • Mol Cell, 2012, 46(5):573-83
S1001 ABT-263 (Navitoclax) ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM, but binds more weakly to Mcl-1 and A1. Phase 1/2.
  • J Clin Invest, 2013, 10.1172/JCI71714
  • Blood, 2011, 117(26):7145-54
  • Blood, 2013, 121(10):1850-7
S1057 Obatoclax Mesylate (GX15-070) Obatoclax (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 1/2.
  • Cancer Res, 2011, 71(13):4494-505
  • Cancer Res, 2011, 10.1158/0008-5472.CAN-10-2668
  • Cancer Res, 2012, 72(11):2814-21
S1121 TW-37 TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM, respectively.
  • Cell Death Differ, 2013, 20(11):1475-84
  • Cell Death Differ, 2012, 19(12):1896-907
  • Cell Death Dis, 2013, 4:e742
S2812 AT101 AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM; does not inhibit BIR3 domain and BID. Phase 1/2.
S8048 ABT-199 (GDC-0199) ABT-199 (GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 2.
  • Cell Death Differ, 2014, 10.1038/cdd.2014.37
S7105 BAM7 BAM 7 is a direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
S8061 Sabutoclax Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
S7200 Apogossypolone (ApoG2) Apogossypolone (ApoG2) is a pan Bcl-2 inhibitor for Bcl-2, Bcl-XL and Mcl-1 with Ki of 35 nM, 660 nM and 25 nM, respectively.
S1071 HA14-1 HA14-1 is a non-peptidic ligand of a Bcl-2 surface pocket with IC50 of ~9 μM.
  • Cancer Res, 2011, 10.1158/0008-5472.CAN-10-2668